PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks). NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks), 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumour size <= 3cm. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab